Pamidronic acid
 | |
| Clinical data | |
|---|---|
| Trade names | Aredia, Pamimed, among others |
| Other names | Pamidronate disodium pentahydrate, pamidronate disodium |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a601163 |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 54% |
| Metabolism | Nil |
| Elimination half-life | 28 ± 7 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.049.897 |
| Chemical and physical data | |
| Formula | C3H11NO7P2 |
| Molar mass | 235.069 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.
It was patented in 1971 and approved for medical use in 1987.[1]
Medical uses[edit]
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder osteogenesis imperfecta. It has been studied in the treatment of complex regional pain syndrome.[2]
Administration[edit]
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.
Side effects[edit]
Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[3]
Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.
Pharmacology[edit]
| Bisphosphonate | Relative potency |
|---|---|
| Etidronate | 1 |
| Tiludronate | 10 |
| Pamidronate | 100 |
| Alendronate | 100-500 |
| Ibandronate | 500-1000 |
| Risedronate | 1000 |
| Zoledronate | 5000 |
References[edit]
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495.
- ^ Kubalek I, Fain O, Paries J, Kettaneh A, Thomas M (December 2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases". Rheumatology. 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.
- ^ Zarychanski R, Elphee E, Walton P, Johnston J (January 2006). "Osteonecrosis of the jaw associated with pamidronate therapy". American Journal of Hematology. 81 (1): 73–75. doi:10.1002/ajh.20481. PMID 16369966. S2CID 11830192.
- ^ Tripathi KD (2013-09-30). Essentials of medical pharmacology (Seventh ed.). New Delhi: Jaypee Brothers Medical Publishers Pvt. Limited. ISBN 9789350259375. OCLC 868299888.
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |